Juvenile Idiopathic Arthritis, Lupus and Rheumatoid Disease

In Australia there are 3.3 million sufferers of general arthritis of which 500,000 are people with rheumatoid disease (including 5,000 children), or about 2% of the population.  The target population in the USA is 1.5 million, 85,000 in New Zealand, 450,000 in Canada and about 1.4 million in the UK.  In Australia, the annual costs of drug supply for a patient with moderate to severe rheumatoid arthritis is estimated at $8,000 to $36,000, depending on the type of medications. 

Rheumatoid Disease can be a significant cause of disability:

  • 2.9 times as likely as those without the condition to report severe or very severe pain; and
  • 3.3 times as likely as those without the condition to report poor health status.

Dragon Claw is being developed for global access for English speaking countries.  We focus on the health and wellness not the drugs and illness.  We do not provide medical advice.

In 2013 the US based Rheumatoid Patient Foundation released a survey report based on over 1,700 responses. For example:

  • 80% reported that they sometimes have low- grade fevers, and 99% reported sometimes experiencing RA-related fatigue
  • On average, respondents experienced only 2 pain-free days per month
  • A quarter of the respondents stated that joint pain and stiffness lasts all day and night and 52% experienced some or most of their joint pain and stiffness in the evening or after a period of activity
  • One in three respondents stated that they ‘always’ or ‘usually’ have RA symptoms that their rheumatologists do not believe.